scholarly journals MRI characterization of focal liver lesions in non-cirrhotic patients: assessment of added value of gadoxetic acid-enhanced hepatobiliary phase imaging

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Bardia Moosavi ◽  
Anuradha S. Shenoy-Bhangle ◽  
Leo L. Tsai ◽  
Robert Reuf ◽  
Koenraad J. Mortele
Keyword(s):  
Gadoxetic Acid ◽  
Added Value ◽  
Rank Test ◽  
Focal Liver Lesions ◽  
Hepatobiliary Phase ◽  
Liver Lesions ◽  
Enhanced Mri ◽  
Phase Images ◽  
Cirrhotic Patients

Abstract Background To evaluate the added value of the hepatobiliary (HPB) phase in gadoxetic acid-enhanced magnetic resonance imaging (MRI) in characterizing newly discovered indeterminate focal liver lesions in non-cirrhotic patients. Results One-hundred and twenty-five non-cirrhotic patients (median age, 46 years; range, 20–85 years; 100 females) underwent gadoxetic acid-enhanced MRI, including the 20-min delayed HPB phase, for characterization of newly discovered focal liver lesions. Images were independently evaluated by two blinded, board-certified abdominal radiologists (R1 and R2) who characterized liver lesions without and with assessment of the HPB phase images in two separate readout sessions. Confidence in diagnosis was scored on a scale from 0 to 3. Inter-observer agreement was assessed using Cohen κ statistics. Change in diagnosis and confidence in diagnosis were evaluated by Wilcoxon signed rank test. There was no significant change in diagnosis before and after evaluation of the HPB phase for both readers (p = 1.0 for R1; p = 0.34 for R2). Confidence in diagnosis decreased from average 2.8 ± 0.45 to 2.6 ± 0.59 for R1 and increased from 2.6 ± 0.83 to 2.8 ± 0.46 for R2. Change in confidence was only statistically significant for R1 (p = 0.003) but not significant for R2 (p = 0.49). Inter-reader agreement in diagnosis was good without (k = 0.66) and with (k = 0.75) inclusion of the HPB phase images. Conclusions The added information obtained from the HPB phase of gadoxetic acid-enhanced MRI does not change the diagnosis or increase confidence in diagnosis when evaluating new indeterminate focal liver lesions in non-cirrhotic patients.

Visibility of focal liver lesions: Comparison between kupffer phase of CEUS with sonazoid and hepatobiliary phase of gadoxetic acid-enhanced MRI

2017 ◽  
Vol 45 (9) ◽  
pp. 542-550
Author(s):  
Woo Young Yang ◽  
Hee Sun Park ◽  
Young Jun Kim ◽  
Mi Hye Yu ◽  
Sung Il Jung ◽  
...  
Keyword(s):  
Gadoxetic Acid ◽  
Focal Liver Lesions ◽  
Hepatobiliary Phase ◽  
Liver Lesions ◽  
Enhanced Mri

scholarly journals Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis

Medicine ◽  
2017 ◽  
Vol 96 (29) ◽  
pp. e7278 ◽  
Author(s):  
Seung Kak Shin ◽  
Yun Soo Kim ◽  
Seung Joon Choi ◽  
Young Sup Shim ◽  
Dong Hae Jung ◽  
...  
Keyword(s):  
Gadoxetic Acid ◽  
Hepatobiliary Phase ◽  
Enhanced Mri ◽  
Hepatic Lesions

scholarly journals Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI

2020 ◽  
Vol 93 (1112) ◽  
pp. 20190989
Author(s):  
Cathryn L Hui ◽  
Marcela Mautone
Keyword(s):  
Liver Parenchyma ◽  
Gadoxetic Acid ◽  
Hepatobiliary Phase ◽  
Liver Lesions ◽  
Enhanced Mri

A variety of patterns of enhancement of liver lesions and liver parenchyma is observed in the hepatobiliary phase (HBP) of gadoxetic acid-enhanced MRI. It is becoming increasingly apparent that many lesions may exhibit HBP enhancement. Much of the literature regarding the role of gadoxetic acid-enhanced MRI in characterising liver lesions is dichotomous, focusing on whether lesions are enhancing or non-enhancing in the HBP, rather than examining the patterns of enhancement. We provide a pattern-based description of HBP enhancement of liver parenchyma and of liver lesions. The role of OATP1B3 transporters, hepatocyte function and lesion composition in influencing patterns of HBP hyperintensity are discussed.

scholarly journals The possibility of applying magnetic resonance imaging with hepatospecific contrast agent.

2018 ◽  
Vol 96 (3) ◽  
pp. 213-221
Author(s):  
Karina K. Lomovtseva ◽  
G. G. Karmazanovsky
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agent ◽  
Gadoxetic Acid ◽  
Focal Liver Lesions ◽  
Hepatobiliary Phase ◽  
Liver Lesions ◽  
Resonance Imaging ◽  
Cross Sectional ◽  
Extracellular Contrast Agent

Nowadays, it is difficult to overestimate the role of cross-sectional imaging in the diagnosis of focal and diffuse liver diseases. In magnetic resonance imaging (MRI) there is a unique opportunity to use hepatospecific contrast agents compared with other visualization techniques. Gadoxetic acid is a hepatospecific magnetic resonance contrast agent which has the extracellular contrast agent properties and hepatotropic property. About half of the administered dose of gadoxetic acid enters into functioning hepatocytes through cell membrane transporters and then is excreted into the bile ducts and sinusoidal space. The obtained hepatobiliary phase provides information about the structural features of the focal liver lesions, improving their detection and differential diagnosis. In addition it allows to assess the anatomical and functional conditions of the hepatobiliary system. This article describes clinical applications of MRI with gadoxetic acid and its benefits, visualization principles of different focal liver lesions in hepatobiliary phase and features of the obtained images.

Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology

2021 ◽  
pp. 028418512110141
Author(s):  
San-Yuan Dong ◽  
Yu-Tao Yang ◽  
Wen-Tao Wang ◽  
Shuo Zhu ◽  
Wei Sun ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Correlation Coefficient ◽  
Tumor Size ◽  
Pearson Correlation ◽  
Gadoxetic Acid ◽  
Arterial Phase ◽  
Hepatobiliary Phase ◽  
Enhanced Mri ◽  
Phase Images ◽  
Mri Sequences

Background Gadoxetic acid-enhanced magnetic resonance imaging (MRI) has been widely used in clinical practice. However, scientific evidence is lacking for recommending a particular sequence for measuring tumor size. Purpose To retrospectively compare the size of hepatocellular carcinoma (HCC) measured on different gadoxetic acid-enhanced MRI sequences using pathology as a reference. Material and Methods A total of 217 patients with single HCC who underwent gadoxetic acid-enhanced MRI before surgery were included. The size of the HCC was measured by two abdominal radiologists independently on the following sequences: T1-weighted; T2-weighted; b-500 diffusion-weighted imaging (DWI); and arterial, portal venous, transitional, and hepatobiliary phases. Tumor size measured on MRI was compared with pathological size by using Pearson correlation coefficient, independent-sample t test, and Bland–Altman plot. Agreement between two readers was evaluated with intraclass correlation coefficient (ICC). Results Correlation between the MR images and pathology was high for both readers (0.899–0.955). Absolute error between MRI and pathologic assessment was lowest on hepatobiliary phase images for both readers (reader 1, 2.8±4.2 mm; reader 2, 3.2±3.4 mm) and highest on arterial phase images for reader 1 (4.9±4.4 mm) and DWI phase images for reader 2 (5.1±4.9 mm). Absolute errors were significantly different for hepatobiliary phase compared with other sequences for both readers (reader 1, P≤0.012; reader 2, P≤0.037). Inter-reader agreements for all sequence measurements were strong (0.971–0.997). Conclusion The performance of gadoxetic acid-enhanced MRI sequences varied with HCC size, and the hepatobiliary phase may be optimal among these sequences.

Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma

2016 ◽  
Vol 27 (6) ◽  
pp. 2610-2618 ◽  
Author(s):  
Chansik An ◽  
Hyungjin Rhee ◽  
Kyunghwa Han ◽  
Jin-Young Choi ◽  
Young-Nyun Park ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Gadoxetic Acid ◽  
Added Value ◽  
Hepatobiliary Phase ◽  
Enhanced Mri
Sign in / Sign up

Export Citation Format

Share Document